Incontinence Labs and Next Steps

Why Does Incontinence Happen?

Urinary incontinence results from a mismatch between bladder storage pressure and urethral closure pressure, and the causes differ by type. Stress incontinence reflects weakened pelvic floor support. Urgency incontinence signals detrusor overactivity. Overflow incontinence points to impaired bladder contractility or outlet obstruction.

The International Continence Society (ICS) classifies incontinence into four primary categories: stress urinary incontinence (SUI), urgency urinary incontinence (UUI), mixed urinary incontinence, and overflow incontinence [1]. Risk factors include parity, obesity (BMI ≥30 increases risk 2- to 4-fold), age, diabetes mellitus, neurologic disease, pelvic surgery, and certain medications such as alpha-blockers and diuretics [2].

A 2008 epidemiologic review published in the Journal of Urology found that moderate-to-severe incontinence affects approximately 7% of women aged 20-39, rising to 17% in women over 60 [3]. In men, incontinence most commonly follows prostatectomy or develops secondary to benign prostatic hyperplasia causing overflow. Identifying the mechanism is the single most important step before choosing treatment, because stress and urgency subtypes respond to fundamentally different interventions.

Medications represent an underrecognized contributor. ACE inhibitors (via cough-induced stress leaks), loop diuretics, sedative-hypnotics, and alpha-adrenergic blockers can each unmask or worsen incontinence. A thorough medication reconciliation should precede any invasive testing [4].

The Initial Clinical Assessment

The first consultation should include a focused history, physical examination, and a 3-day bladder diary. These three components correctly classify incontinence type in roughly 80% of cases without any advanced testing [5].

History components: onset, duration, triggers (cough, urgency, positional), frequency, nocturia, pad usage, fluid intake pattern, obstetric history, prior pelvic surgery, neurologic symptoms, and current medications. The validated ICIQ-SF (International Consultation on Incontinence Questionnaire-Short Form) quantifies symptom severity in four questions and is recommended by NICE guidelines as a standardized assessment tool [6].

Physical examination includes abdominal palpation for bladder distension, pelvic exam assessing vaginal atrophy and prolapse (POP-Q staging), cough stress test with a comfortably full bladder, and a focused neurologic screen (perineal sensation, anal tone, bulbocavernosus reflex). The 2017 AUA/SUFU guideline states that a positive cough stress test in the office has a sensitivity of 85-90% for confirming stress incontinence and may be sufficient for diagnosis in uncomplicated cases [7].

Bladder diary: Patients record void times, volumes, fluid intake, pad changes, and leak episodes over 72 hours. This tool identifies polyuria (total output greater than 3 L/day), nocturnal polyuria (nocturnal output exceeding 33% of 24-hour total), and provides objective leak frequency. The EAU guidelines recommend the bladder diary as a mandatory component of initial evaluation [8].

Laboratory Tests: What Blood and Urine Reveal

A urinalysis is the single mandatory lab test for every patient presenting with incontinence. Beyond that, targeted bloodwork addresses specific clinical questions rather than serving as a screening battery.

Urinalysis and urine culture: Rules out urinary tract infection (present in 5-10% of women presenting with new urgency incontinence), glycosuria suggesting undiagnosed diabetes, hematuria requiring further workup, and proteinuria indicating renal pathology [7]. Pyuria without bacteriuria may suggest interstitial cystitis or urethritis.

Serum creatinine and eGFR: Indicated when overflow incontinence, bilateral hydronephrosis, or chronic retention is suspected. The AUA recommends renal function testing for patients with high post-void residuals or known obstructive uropathy [7].

Fasting glucose or HbA1c: Uncontrolled diabetes causes osmotic diuresis and diabetic cystopathy. A 2005 longitudinal analysis in Diabetes Care (N=1,461) showed that women with type 2 diabetes had a 70% increased odds of weekly incontinence compared to non-diabetic controls (OR 1.7 to 95% CI 1.2-2.4) [9].

Serum calcium: Hypercalcemia causes polyuria and may present as urgency or frequency mimicking overactive bladder. Check this in patients with concurrent bone pain, fatigue, or constipation.

PSA (men): When overflow incontinence or obstructive symptoms suggest BPH or prostate malignancy, PSA measurement guides further urologic evaluation.

Urine cytology: Reserved for patients with unexplained hematuria, risk factors for bladder cancer (smoking history, occupational chemical exposure, age over 50), or treatment-refractory urgency symptoms.

Post-Void Residual and Imaging

Post-void residual (PVR) measurement determines whether the bladder empties adequately. Portable bladder ultrasound provides a non-invasive PVR in under 60 seconds.

Normal PVR is less than 50 mL. Values between 50-200 mL are equivocal and should be repeated. Values consistently exceeding 200 mL indicate incomplete emptying and raise suspicion for overflow incontinence, detrusor underactivity, or bladder outlet obstruction [7]. The 2019 NICE guideline on urinary incontinence recommends PVR measurement before starting antimuscarinic therapy, as these drugs can worsen retention in susceptible patients [6].

Renal ultrasound is indicated when PVR is elevated, serum creatinine is abnormal, or pelvic mass is suspected. It identifies hydronephrosis, renal calculi, or structural anomalies contributing to obstruction.

Pelvic ultrasound or MRI may be ordered to evaluate pelvic organ prolapse, periurethral masses, or urethral diverticula. MRI provides superior soft-tissue resolution for complex cases, including suspected fistulae following obstetric injury or pelvic radiation [10].

Cystoscopy is not routine but is indicated for microscopic or gross hematuria, recurrent UTIs with incontinence, suspected foreign body, or refractory symptoms that do not respond to empiric treatment after 6-8 weeks. The EAU states that cystoscopy adds diagnostic yield primarily in patients with hematuria or abnormal cytology [8].

Urodynamic Testing: When and Why

Urodynamics is not required for straightforward stress or urgency incontinence responding to conservative measures. It becomes necessary when the diagnosis is unclear, symptoms are mixed, prior treatment has failed, or surgery is being considered.

The VALUE trial (N=222), published in the New England Journal of Medicine in 2012, randomized women with uncomplicated, demonstrable stress incontinence to office evaluation alone versus office evaluation plus urodynamics before surgery. Surgical outcomes were equivalent between groups (success rate 76.9% vs. 77.2% at 12 months), demonstrating that urodynamics did not improve outcomes for straightforward stress incontinence [11].

However, for mixed incontinence, neurogenic bladder, prior failed anti-incontinence surgery, or symptoms discordant with examination findings, the AUA/SUFU guideline recommends multichannel urodynamics including cystometry, pressure-flow studies, and leak-point pressure measurement [7].

Components of a standard urodynamic study include:

• Uroflowmetry: Non-invasive measurement of flow rate and voiding pattern. A maximum flow rate below 15 mL/s suggests possible obstruction or weak detrusor.
• Filling cystometry: Detects involuntary detrusor contractions (detrusor overactivity) and assesses bladder compliance and capacity.
• Abdominal leak point pressure (ALPP): Values below 60 cm H₂O suggest intrinsic sphincter deficiency; values above 90 cm H₂O indicate urethral hypermobility as the primary mechanism [7].
• Pressure-flow study: Differentiates bladder outlet obstruction from detrusor underactivity in patients with elevated PVR.

The 2023 EAU guidelines state: "Urodynamics should be performed when the findings are likely to change management" [8]. This principle prevents unnecessary invasive testing while ensuring appropriate patients receive the information needed for surgical planning.

Conservative and Behavioral Treatments

Pelvic floor muscle training (PFMT) is the first-line intervention for stress incontinence and a co-first-line intervention for urgency incontinence. A 2018 Cochrane review (N=31 trials, 1,817 women) concluded that women receiving PFMT were eight times more likely to report cure of stress incontinence compared to controls (RR 8.38 to 95% CI 3.68-19.07) [12].

Bladder training is the primary behavioral intervention for urgency incontinence. Patients progressively extend voiding intervals from their baseline (often every 1-2 hours) toward a 3- to 4-hour schedule over 6-12 weeks. A randomized trial by Fantl et al. showed a 57% reduction in incontinence episodes with bladder training alone [13].

Weight loss provides measurable benefit. The PRIDE trial (N=338) demonstrated that an 8% reduction in body weight reduced stress incontinence episodes by 47% compared to 28% in controls over 6 months [14]. For patients with BMI ≥30, weight management should be discussed alongside any other intervention.

Fluid management: Reducing caffeine intake and moderating total fluid volume (targeting 1.5-2 L/day) may reduce urgency episodes by 25-30%, per a 2016 randomized crossover trial in BJU International [15].

Timed voiding and prompted voiding are particularly useful for older adults or those with cognitive impairment. These strategies reduce wet episodes by 30-40% in institutional settings [8].

Pharmacotherapy Options

When behavioral interventions provide insufficient improvement after 8-12 weeks, medication becomes appropriate. Drug selection depends entirely on incontinence type.

For urgency incontinence (overactive bladder):

Antimuscarinics (oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, trospium) block M3 receptors on detrusor smooth muscle. A meta-analysis in the Journal of Urology (2012) found that antimuscarinics reduce daily urgency episodes by 1.5-2.0 compared to placebo, with a number needed to treat of 7-8 for achieving continence [16]. Dry mouth (20-30%) and constipation (10-15%) are the most common adverse effects. Extended-release formulations and transdermal oxybutynin reduce anticholinergic side effects.

Dr. Phillip Wein, former editor of Campbell-Walsh Urology, has noted: "The ideal antimuscarinic would selectively target the bladder during filling without affecting other organ systems. Current agents are not organ-selective, which explains their side-effect profile."

Mirabegron (Myrbetriq), a beta-3 adrenoreceptor agonist, offers an alternative mechanism. The SCORPIO trial (N=1,978) showed that mirabegron 50 mg reduced incontinence episodes by 1.57/day versus 1.17/day for placebo (P<0.05) with a lower rate of dry mouth (2.8% vs. 0.5% placebo) compared to antimuscarinics [17]. The FDA approved vibegron (Gems) in 2020 as a second beta-3 agonist option.

The 2019 AUA/SUFU OAB guideline recommends: "Clinicians should offer oral antimuscarinics or oral beta-3 agonists as second-line therapy" [7].

For stress incontinence:

No FDA-approved pharmacotherapy exists specifically for stress incontinence in the United States. Duloxetine (a serotonin-norepinephrine reuptake inhibitor) is approved in Europe for moderate-to-severe SUI. A Cochrane review showed duloxetine reduces incontinence episode frequency by 50% in 47-52% of patients versus 33-40% for placebo, but discontinuation due to adverse effects (nausea, fatigue) occurs in 13% [18]. Topical vaginal estrogen improves urethral mucosal coaptation in postmenopausal women and can be combined with PFMT [6].

Procedural and Surgical Interventions

For patients who do not achieve adequate control with conservative and pharmacologic measures, several procedural options exist with strong evidence bases.

OnabotulinumtoxinA (Botox) injection: The FDA approved 100 units of intradetrusor Botox for refractory OAB in 2013. A key trial (N=557) demonstrated that 22.9% of patients achieved complete continence versus 6.5% for placebo at 12 weeks [19]. Effects last 6-9 months, requiring repeat injections. The primary risk is urinary retention (5-6%), so patients must be counseled about possible intermittent self-catheterization.

Sacral neuromodulation (InterStim): Implantable sacral nerve stimulator approved for refractory urgency incontinence. The InSite trial showed 61% of patients achieved greater than 50% reduction in daily leaks at 6 months [20]. Battery life with the rechargeable InterStim II Micro is approximately 15 years.

Midurethral sling (for stress incontinence): The retropubic tension-free vaginal tape (TVT) and transobturator tape (TOT) are the standard surgical treatments. A 2015 Cochrane review (N=12,113 across 81 trials) reported objective cure rates of 80-90% at 1 year for both approaches, with no significant difference between routes [21]. Long-term data from the TOMUS trial (N=597) showed 51.3% (TVT) and 38.8% (TOT) objective cure at 5 years by strict composite outcome criteria [22].

Dr. Christopher Chapple, former chair of the EAU Guideline Panel on Urinary Incontinence, stated: "The synthetic midurethral sling remains the gold standard surgical treatment for stress urinary incontinence when conservative measures have been exhausted."

Bulking agents: Periurethral injection of bulking agents (Bulkamid hydrogel) offers a minimally invasive alternative for women who prefer to avoid mesh or are poor surgical candidates. Cure rates are lower (30-50%) but the procedure can be performed under local anesthesia in the office [8].

Artificial urinary sphincter (men): For post-prostatectomy incontinence persisting beyond 12 months, the AMS 800 artificial sphincter achieves social continence (0-1 pad/day) in 61-100% of patients [7].

Red Flags Requiring Urgent Referral

Not all incontinence can be managed in primary care. Certain findings should prompt immediate specialist referral.

Hematuria with incontinence requires cystoscopy to exclude bladder malignancy. New-onset incontinence with neurologic symptoms (saddle anesthesia, lower extremity weakness, bowel dysfunction) may indicate cauda equina syndrome and warrants same-day MRI and neurosurgical consultation [6]. Pelvic mass on examination, recurrent symptomatic UTIs (three or more per year), suspected fistula (constant leaking after recent surgery or radiation), and incontinence in children beyond expected toilet training age all require specialist evaluation.

The AUA guideline recommends referral to a specialist when: initial treatment has failed after 8-12 weeks, the diagnosis is uncertain, surgical management is being considered, or when hematuria, recurrent infections, or elevated PVR complicate the clinical picture [7].

Patients taking GLP-1 receptor agonists (semaglutide, tirzepatide) for weight management may observe improvement in incontinence as BMI decreases. The STEP-1 trial (N=1,961) demonstrated 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg [23]. Given the established relationship between BMI and incontinence severity, clinicians should reassess incontinence endpoints as weight changes during treatment.